EGFR and breast cancer: In addition, ERBB2 somatic mutations have been identified in ERBB gene-amplification-negative human breast cancers; many of these are activating mutations, and thus, ERBB2 somatic mutation is an alternative mechanism to activate HER2 in breast cancer [189].